Executive Summary
The PTAB issued a Final Written Decision finding numerous claims of Smith Interface Technologies unpatentable over the combination of Hotelling, Martyn, and Cho. The Board adopted a specific definition for POSITA, requiring computer science expertise with professional GUI experience.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Apple Inc. vs Smith Interface Technologies, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Abbott Laboratories et al.vsMIRACOR MEDICAL SA
Abbott Laboratories successfully petitioned to challenge MIRACOR MEDICAL SA's cardiac assist pump patent based on obviousness (35 U.S.C. § 103). The PTAB institution decision found sufficient evidence of unpatentability over the Bourque/Wampler combination, despite arguments regarding specific claim limitations and prior art scope.
Ericsson Inc. et al.vsXR COMMUNICATIONS LLC
The PTAB issued a Final Written Decision finding all 17 challenged claims unpatentable under 35 U.S.C. § 103(a). The Board determined that the prior art reference Trigui disclosed sufficient elements, rendering the claimed MIMO/Beamforming technology obvious to a person having ordinary skill in the art (PHOSITA).
Apple Inc.vsSmith Interface Technologies, LLC
Apple Inc. petitioned the PTAB challenging U.S. Patent No. 10,656,754 on touchscreen gesture and display effects. The petitioner argues that the claims are obvious over a combination of Ahn and Chaudhri '842, specifically regarding blurring background elements based on touch gestures. The petition was deemed compelling enough to warrant institution.
Sarepta Therapeutics, Inc. et al.vsGenzyme Corporation et al.
The USPTO Board denied the institution of IPR proceedings (IPR2025-01194) involving Sarepta Therapeutics and Genzyme Corporation, meaning no trial will proceed on the challenged patent.
Azurity Pharmaceuticals, Inc.vsEXELIXIS, INC.
Azurity Pharmaceuticals failed to convince the PTAB that EXELIXIS's drug formulation patent was unpatentable, resulting in a denial of institution for IPR2025-00210. The Board rejected anticipation arguments based on prior art family relationships and dismissed obviousness claims regarding impurity control.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.